等待开盘 04-01 09:30:00 美东时间
-0.210
-1.10%
今日重点评级关注:HC Wainwright & Co.:维持Perspective Therapeutics"买入"评级,目标价从12美元升至13美元;Litchfield Hills:维持Star Equity Holdings"买入"评级,目标价从21美元升至28美元
03-24 10:07
今日重点评级关注:韦德布什:维持Black Diamond Therapeutic"跑赢大市"评级,目标价从13美元升至14美元;花旗:维持Olema Pharmaceuticals"买入"评级,目标价从60美元升至62美元
03-18 10:48
Raymond James analyst RJ Milligan downgrades Netstreit (NYSE:NTST) from Strong Buy to Outperform and raises the price target from $21 to $22.
03-17 23:34
今日重点评级关注:LUCID CAPITAL MARKETS:上调INmune Bio评级至"买入" 目标价从2美元升至9美元;Clear Street:维持MoonLake Immunotherapeutics Class A"买入"评级,目标价从45美元升至70美元
03-12 12:34
今日重点评级关注:Evercore ISI集团:维持Caribou Biosciences"跑赢大市"评级,目标价从11美元升至13美元;富国银行:上调uniQure评级至"超配",目标价从15美元升至60美元
03-10 15:05
UBS analyst Michael Goldsmith maintains Netstreit (NYSE:NTST) with a Buy and raises the price target from $21 to $24.
03-10 04:27
今日重点评级关注:HC Wainwright & Co.:维持NRX Pharmaceuticals"买入"评级,目标价从40美元升至45美元;RBC Capital:维持NUVATION BIO"跑赢大市"评级,目标价从12美元升至13美元
03-04 10:22
Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raised to $28, MDB cut to $260, RIOT cut to $23, DAVE raised to $295, NTST raised to $22, U raised to $19, TREE cut to $290.
03-03 21:37
今日重点评级关注:HC Wainwright & Co.:维持Helus Pharma"买入"评级,目标价从55美元升至95美元;HC Wainwright & Co.:维持Compass Pathways"买入"评级,目标价从40美元升至70美元
03-03 20:22
Scotiabank analyst Nicholas Yulico maintains Netstreit (NYSE:NTST) with a Sector Outperform and raises the price target from $21 to $22.
03-03 01:53